Cargando…
Ocrelizumab zur Behandlung der Multiplen Sklerose
Ocrelizumab is a monoclonal antibody directed against the differentiation antigen CD20, which leads to an effective long-term depletion of lymphocytes, in particular B cells. Recently published phase 3 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclero...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Medizin
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286209/ https://www.ncbi.nlm.nih.gov/pubmed/32524163 http://dx.doi.org/10.1007/s00115-020-00937-6 |